Expert OpinionAnalyst reiterates Buy rating based on solid quarterly results, encouraging FY24 guidance, and potential for margin improvement.
Financial PerformanceThe assets acquired are expected to contribute approximately $100MM in annual revenue, indicating potential for growth.
Mergers And AcquisitionsManagement continues to pursue accretive acquisitions, including its latest deal to acquire assets from OPK/Bio-Reference Labs.